tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Neurocrine (NBIX)
NASDAQ:NBIX
US Market
NBIX
Neurocrine
RESEARCH TOOLSreports

Neurocrine (NBIX) Stock News & Sentiment

Compare
1,546 Followers
Neurocrine Biosciences: Ingrezza-Driven Strength and Risk-Balanced Pipeline Support Buy Rating Despite Valbenazine Setback
Premium
Ratings
Neurocrine Biosciences: Ingrezza-Driven Strength and Risk-Balanced Pipeline Support Buy Rating Despite Valbenazine Setback
19d ago
NBIX
Buy Rating Reaffirmed on Neurocrine: Limited Impact from Trial Setback, Strength in Core Execution and Deep Pipeline Upside
Premium
Ratings
Buy Rating Reaffirmed on Neurocrine: Limited Impact from Trial Setback, Strength in Core Execution and Deep Pipeline Upside
19d ago
NBIX
Neurocrine Biosciences Launches Phase 2 Trial for Bipolar I Disorder Treatment
Premium
Company Announcements
Neurocrine Biosciences Launches Phase 2 Trial for Bipolar I Disorder Treatment
25d ago
NBIX
Neurocrine Biosciences Advances Schizophrenia Treatment with New Phase 2a Clinical Study
Premium
Company Announcements
Neurocrine Biosciences Advances Schizophrenia Treatment with New Phase 2a Clinical Study
25d ago
NBIX
Neurocrine’s Strategic Growth and Innovation: Analyst Upgrades Price Target to $198 with Buy Rating
Premium
Ratings
Neurocrine’s Strategic Growth and Innovation: Analyst Upgrades Price Target to $198 with Buy Rating
25d ago
NBIX
Neurocrine Biosciences: Strong R&D Pipeline and Strategic Advancement in Neuropsychiatry and Obesity Treatment
Premium
Ratings
Neurocrine Biosciences: Strong R&D Pipeline and Strategic Advancement in Neuropsychiatry and Obesity Treatment
25d ago
NBIX
Buy Rating: Unlocking Neurocrine Biosciences’ Long-Term Growth Potential Through Diversified Pipeline
Premium
Ratings
Buy Rating: Unlocking Neurocrine Biosciences’ Long-Term Growth Potential Through Diversified Pipeline
25d ago
NBIX
More NBIX News >

NBIX News on the Web

Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks News
Neutral
RBC Capital would be a buyer of Neurocrine on weakness following competitor data
The Fly
Neutral
Neurocrine : Phase 3 Study Of Valbenazine In Dyskinetic Cerebral Palsy Fails To Meet Main Goal
rttnews
Neutral
Here are Citi's top market sectors for 2026 and 3 stock picks for each one
Markets Insider
Neutral
RBC Capital Keeps Their Buy Rating on Neurocrine (NBIX)
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: Cigna (CI), Neurocrine (NBIX) and Roche Holding AG (OtherRHHVF)
TipRanks News
Neutral
Here is Why Growth Investors Should Buy Neurocrine (NBIX) Now
Zacks
Bullish
Why Neurocrine Biosciences, Inc.’s (NBIX) Stock Is Up 5.64%
AAII
Neutral

News Score - Last 7 Days

Neutral
NBIX
Sector Average
Media Buzz
This Week2 articles
Weekly Average1.25 articles
News Sentiment
This Week50%
Sector Average59%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is NBIX’s Media Buzz Sentiment?
2 articles about NBIX were published this week. In an average week, 1.25 articles are published.
    What is NBIX’s weekly average amount of articles?
    In an average week, 1.25 articles about NBIX are published.
      What is NBIX’s News Sentiment?
      50% of articles about NBIX were positive this week, compared to its sector average of 59%.
        Healthcare Stocks that are Trending in the News
        RVMDRevolution Medicines
        REGNRegeneron
        KRYSKrystal Biotech
        GNPXGenprex
        RIGLRigel
        Showing the stocks with the most bullish news sentiment over the past week